ADAR
ADAR (adenosine deaminase RNA specific, also known as ADAR1, DRADA, IFI4 and G1P1) is the enzyme that carries out A-to-I editing of double-stranded RNA. By converting adenosine to inosine, it alters how cellular and viral RNAs are read, spliced and stabilised. Browse Assay Genie's current range of ADAR research reagents below, or read on for the biology behind the target.
ADAR catalyses the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA), a process known as A-to-I RNA editing. Because the translational machinery reads inosine as guanosine, editing can change codons and therefore protein sequence. It can also alter pre-mRNA splicing by changing splice site recognition sequences, affect RNA stability by changing sequences recognised by nucleases, and influence structure-dependent activities such as microRNA production or targeting and protein-RNA interactions. The enzyme can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing), and it acts on both viral and cellular RNAs.
Cellular substrates include bladder cancer-associated protein (BLCAP) and transcripts for the glutamate receptor GRIA2, the serotonin receptor HTR2C and the GABA receptor subunit GABRA3. Site-specific editing of these transcripts produces amino acid substitutions that change the functional activity of the encoded proteins. ADAR edits GRIA2 only at a low level at the Q/R site, but edits efficiently at the R/G site and HOTSPOT1. The ADAR protein is annotated in the cytoplasm, the nucleus and the nucleolus, and the gene is placed in the HGNC group of adenosine deaminases acting on RNA.
ADAR also shapes viral infection, with effects that depend on the virus. It is proviral for hepatitis delta virus, measles virus, vesicular stomatitis virus and HIV-1, and antiviral for hepatitis C virus, where editing at multiple sites impairs replication. For measles and vesicular stomatitis viruses it acts independently of editing, by suppressing EIF2AK2/PKR activation, and for HIV-1 it acts by both routes. In hepatitis delta virus, editing at the amber/W site permits synthesis of the large delta antigen, although high levels of ADAR1 inhibit replication. The gene was formerly named interferon-induced protein 4, and mutations in it have been associated with dyschromatosis symmetrica hereditaria. Alternative splicing gives multiple transcript variants.
ADAR is the enzyme behind A-to-I editing, which can change codons, splice sites, RNA stability and microRNA production or targeting.
ADAR edits transcripts for GRIA2, HTR2C and GABRA3, producing amino acid substitutions that alter receptor function.
ADAR edits viral RNAs from HCV, HDV, measles virus, VSV and HIV-1, with proviral or antiviral outcomes depending on the virus.
Mutations in the ADAR gene have been associated with dyschromatosis symmetrica hereditaria, making it a focus for genetic studies.
ADAR catalyses the deamination of adenosine to inosine in double-stranded RNA. This A-to-I editing can change codons, splicing, RNA stability and RNA structure, and it affects both cellular and viral RNAs, either at specific sites or at many sites (hyper-editing).
ADAR is also called ADAR1, DRADA, IFI4 and G1P1, and its previous name was interferon-induced protein 4. UniProt lists the protein as double-stranded RNA-specific adenosine deaminase. Alternative splicing of the ADAR gene results in multiple transcript variants.
Mutations in the ADAR gene have been associated with dyschromatosis symmetrica hereditaria. Orthologues named Adar exist in mouse and rat. Check the datasheet of any product for its validated reactivity.
Substrates of ADAR editing and the PKR kinase it regulates, including neurotransmitter receptors and related RNA-editing targets.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P55265; product specifications from Assay Genie datasheets.